Subgroup analysis of phase 3 studies of dulaglutide in Japanese patients with type 2 diabetes

The efficacy and tolerability of once weekly dulaglutide 0.75 mg in Japanese patients with type 2 diabetes (T2D) were evaluated by subgroups defined by key demographic characteristics. This post hoc analysis included data from patients who received dulaglutide 0.75 mg for up to 26 weeks in three pha...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Endocrine Journal 2016, Vol.63(3), pp.263-273
Hauptverfasser:	Onishi, Yukiko, Oura, Tomonori, Nishiyama, Hiroshi, Ohyama, Sumika, Takeuchi, Masakazu, Iwamoto, Noriyuki
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Biguanides - administration & dosage Biguanides - adverse effects Biguanides - therapeutic use Body Mass Index Combined Modality Therapy - adverse effects Diabetes Mellitus, Type 2 - blood Diabetes Mellitus, Type 2 - complications Diabetes Mellitus, Type 2 - drug therapy Diabetes Mellitus, Type 2 - therapy Double-Blind Method Drug Administration Schedule Drug Therapy, Combination - adverse effects Dulaglutide Female GLP-1 receptor agonist Glucagon-Like Peptide-1 Receptor - agonists Glucagon-Like Peptide-1 Receptor - metabolism Glucagon-Like Peptides - administration & dosage Glucagon-Like Peptides - adverse effects Glucagon-Like Peptides - analogs & derivatives Glucagon-Like Peptides - therapeutic use Glycated Hemoglobin A - analysis Humans Hyperglycemia - prevention & control Hypoglycemia - chemically induced Hypoglycemia - epidemiology Hypoglycemia - prevention & control Hypoglycemic Agents - administration & dosage Hypoglycemic Agents - adverse effects Hypoglycemic Agents - therapeutic use Immunoglobulin Fc Fragments - administration & dosage Immunoglobulin Fc Fragments - adverse effects Immunoglobulin Fc Fragments - therapeutic use Male Middle Aged Nausea - chemically induced Nausea - epidemiology Overweight - complications Overweight - diet therapy Overweight - therapy Recombinant Fusion Proteins - administration & dosage Recombinant Fusion Proteins - adverse effects Recombinant Fusion Proteins - therapeutic use Subgroup analysis Sulfonylurea Compounds - administration & dosage Sulfonylurea Compounds - adverse effects Sulfonylurea Compounds - therapeutic use Type 2 diabetes Weight Loss - drug effects
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The efficacy and tolerability of once weekly dulaglutide 0.75 mg in Japanese patients with type 2 diabetes (T2D) were evaluated by subgroups defined by key demographic characteristics. This post hoc analysis included data from patients who received dulaglutide 0.75 mg for up to 26 weeks in three phase 3 trials (one open-label, randomized; one double-blind and open-label, randomized; one open-label, nonrandomized). Patients were classified into subgroups on the basis of sex (male, female), age (
ISSN:	0918-8959 1348-4540
DOI:	10.1507/endocrj.EJ15-0518